Libevitug - Huahui Health
Alternative Names: HH-003Latest Information Update: 28 Jan 2026
At a glance
- Originator Huahui Health
- Class Antiretrovirals; Antivirals; Monoclonal antibodies
- Mechanism of Action Hepatitis B surface antigen presurface protein 1 inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Hepatitis D
- Discontinued Hepatitis B
Most Recent Events
- 28 Jan 2026 Discontinued - Phase-II for Hepatitis B (Combination therapy, Treatment-experienced) in China (IV), before January 2026 (Huahui Health pipeline, January 2026)
- 28 Jan 2026 Discontinued - Phase-II for Hepatitis B in China (IV), before January 2026 (Huahui Health pipeline, January 2026)
- 28 Jan 2026 Phase-II clinical trials in Hepatitis D in Mongolia, Pakistan (IV), before January 2026 (Huahui Health pipeline, January 2026)